Malignant pheochromocytoma: Current status and initiatives for future progress

Graeme Eisenhofer, Stefan R. Bornstein, Frederieke M. Brouwers, Nai Kong V Cheung, Patricia L. Dahia, Ronald R. De Krijger, Thomas J. Giordano, Lloyd A. Greene, David S. Goldstein, Hendrik Lehnert, William M. Manger, John M. Maris, Hartmut P H Neumann, Karel Pacak, Barry L. Shulkin, David I Smith, Arthur S. Tischler, William Francis Young

Research output: Contribution to journalArticle

260 Scopus citations

Abstract

Pheochromocytomas are rare catecholamine-producing neuroendocrine tumors that are usually benign, but which may also present as or develop into a malignancy. Predicting such behavior is notoriously difficult and there are currently no curative treatments for malignant tumors. This report follows from a workshop at the Banbury Conference Center, Cold Spring Harbor, New York, on the 16th-18th November 2003, held to review the state of science and to facilitate future progress in the diagnosis and treatment of malignant pheochromocytoma. The rarity of the tumor and the resulting fragmented nature of studies, typically involving small numbers of patients, represent limiting factors to the development of effective treatments and diagnostic or prognostic markers for malignant disease. Such development is being facilitated by the availability of new genomics-based tools, but for such approaches to succeed ultimately requires comprehensive clinical studies involving large numbers of patients, stringently collected clinical data and tumor samples, and interdisciplinary collaborations among multiple specialist centers. Nevertheless, the well-characterized hereditary basis and the unique functional nature of these neuroendocrine tumors provide a useful framework that offers advantages for establishing the pathways of tumorigenesis and malignancy. Such findings may have relevance for understanding the basis of other more common malignancies where similar frameworks are not available. As the relevant pathways leading to pheochromocytoma are established it should be possible to take advantage of the new generation of drugs being developed to target specific pathways in other malignancies. Again the success of this will require well-designed and coordinated multicenter studies.

Original languageEnglish (US)
Pages (from-to)423-436
Number of pages14
JournalEndocrine-Related Cancer
Volume11
Issue number3
DOIs
StatePublished - Sep 2004

    Fingerprint

ASJC Scopus subject areas

  • Endocrinology
  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism

Cite this

Eisenhofer, G., Bornstein, S. R., Brouwers, F. M., Cheung, N. K. V., Dahia, P. L., De Krijger, R. R., Giordano, T. J., Greene, L. A., Goldstein, D. S., Lehnert, H., Manger, W. M., Maris, J. M., Neumann, H. P. H., Pacak, K., Shulkin, B. L., Smith, D. I., Tischler, A. S., & Young, W. F. (2004). Malignant pheochromocytoma: Current status and initiatives for future progress. Endocrine-Related Cancer, 11(3), 423-436. https://doi.org/10.1677/erc.1.00829